jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Female Hormone Profile

Hormone/ Element

6 parameters

image

Report in 48Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Includes AMH, FSH, estradiol, etc.

₹9,999₹14,474

31% OFF

Parameters

  • List of Tests
    • Estradiol
    • FSH
    • LH
    • AMH
    • Inhibin - B
    • Anti Ovarian Antibody (AOA)

Female Hormone Profile

  • Why is it done?
    • Evaluates reproductive hormonal function and ovarian reserve in women of childbearing age and those experiencing menopause
    • Estradiol measures primary estrogen levels to assess follicular development and endometrial preparation during menstrual cycles
    • FSH (Follicle-Stimulating Hormone) and LH (Luteinizing Hormone) assess pituitary-ovarian axis function and regulate ovulation and menstrual cycle phases
    • AMH (Anti-Müllerian Hormone) evaluates ovarian reserve and predicts response to fertility treatments
    • Inhibin-B indicates ovarian follicle maturity and is critical for menstrual cycle regulation
    • Anti-Ovarian Antibody (AOA) screens for autoimmune ovarian dysfunction that may impair fertility
    • Indicated for infertility evaluation, irregular menstrual cycles, suspected early menopause, polycystic ovary syndrome (PCOS), ovarian dysfunction assessment, and fertility treatment planning
    • Optimal timing: Days 3-5 of menstrual cycle for basal hormone levels (Estradiol, FSH, LH, Inhibin-B), while AMH can be tested any day of the cycle
    • Tests work synergistically to provide comprehensive assessment of ovarian function, hormonal reserve, and reproductive potential
  • Normal Range
    • Estradiol (E2): Follicular phase 15-60 pg/mL; Ovulatory phase 200-400 pg/mL; Luteal phase 50-150 pg/mL; Postmenopausal <20 pg/mL (or 55-220 pmol/L follicular phase in SI units)
    • FSH (Follicle-Stimulating Hormone): Follicular phase 3.0-8.0 mIU/mL; Ovulatory phase 9.0-26.0 mIU/mL; Luteal phase 1.5-5.0 mIU/mL; Postmenopausal 25-100+ mIU/mL
    • LH (Luteinizing Hormone): Follicular phase 1.7-8.6 mIU/mL; Ovulatory phase 25.8-96.5 mIU/mL; Luteal phase 0.4-20.0 mIU/mL; Postmenopausal 10.9-58.0 mIU/mL
    • AMH (Anti-Müllerian Hormone): 1.0-4.0 ng/mL indicates good ovarian reserve; 0.6-1.0 ng/mL indicates fair reserve; 0.0-0.6 ng/mL indicates low reserve; >4.0 ng/mL may suggest PCOS or increased reserve
    • Inhibin-B: Follicular phase 43-204 pg/mL; Luteal phase and postmenopausal <5 pg/mL. Higher levels in follicular phase indicate normal ovarian function
    • Anti-Ovarian Antibody (AOA): Negative or <12 IU/mL is normal; Positive or ≥12 IU/mL indicates presence of autoimmune antibodies against ovarian tissue
    • Normal results indicate intact hypothalamic-pituitary-ovarian (HPO) axis function and adequate ovarian reserve with normal follicle development capability
    • Abnormal results require interpretation in context of menstrual cycle phase, age, and clinical symptoms; cycle day 3 testing provides baseline comparison
  • Interpretation
    • Estradiol Interpretation: Low levels (<15 pg/mL) suggest ovarian failure, premature menopause, or severe ovarian dysfunction; Elevated levels (>60 pg/mL follicular phase) may indicate estrogen-secreting tumors or hyperstimulation; Cycle phase timing critical for accurate interpretation
    • FSH Interpretation: Elevated FSH (>8-10 mIU/mL on day 3) indicates ovarian insufficiency, diminished ovarian reserve, or approaching menopause; Very high levels (>30 mIU/mL) suggest ovarian failure; Low FSH indicates pituitary insufficiency or hypothalamic dysfunction
    • LH Interpretation: Elevated LH with normal FSH may suggest PCOS (LH:FSH ratio >2.5-3.0); Low LH indicates hypogonadotropic hypogonadism; Absence of LH surge at mid-cycle suggests anovulation; LH levels help assess reproductive hormone balance
    • AMH Interpretation: Values >4.0 ng/mL suggest good to excellent ovarian reserve and favorable fertility outcomes; 1.0-4.0 ng/mL indicates adequate reserve; <1.0 ng/mL suggests diminished ovarian reserve with potentially reduced fertility; <0.3 ng/mL indicates severely diminished reserve; Levels <0.1 ng/mL may indicate ovarian failure
    • Inhibin-B Interpretation: Low inhibin-B on day 3 (<43 pg/mL) suggests poor ovarian reserve and reduced fertility potential; Undetectable inhibin-B indicates absent follicular development; Normal levels confirm adequate follicle development and ovarian function; Levels correlate with ovarian reserve status
    • Anti-Ovarian Antibody (AOA) Interpretation: Positive result (≥12 IU/mL) indicates autoimmune-mediated ovarian dysfunction; Associated with autoimmune ovarian failure, premature ovarian insufficiency, and increased miscarriage risk; Negative result excludes antibody-mediated autoimmune ovarian disease; Testing may guide immunosuppressive therapy consideration
    • Combined Pattern Analysis: FSH:Estradiol ratio helps predict ovarian reserve (FSH >10 with low E2 suggests poor reserve); FSH:LH ratio abnormalities indicate specific HPO axis dysfunction; Rising AMH with normal FSH indicates preserved ovarian function; Multiple abnormal markers suggest severe reproductive compromise
    • Factors affecting interpretation: Cycle day timing critical for accurate assessment; Age-specific reference ranges differ; Hormonal contraceptive use suppresses results; Thyroid disease affects hormone levels; Chronic illness and stress alter hormone patterns; PCOS presents distinctive hormone profiles
  • Associated Organs
    • Pituitary Gland: Primary producer of FSH and LH through gonadotroph cells; Abnormalities cause secondary hypogonadism; FSH/LH ratios reflect pituitary function; Pituitary adenomas and hypopituitarism cause hormone deficiencies
    • Hypothalamus: Controls pituitary hormone release via GnRH (Gonadotropin-Releasing Hormone); Dysfunction impairs hormone pulsatility; Stress, obesity, and metabolic disorders affect hypothalamic function; Hypothalamic amenorrhea presents with low FSH/LH pattern
    • Ovaries: Primary organ evaluated; Produces estradiol, progesterone, AMH, and inhibin-B from developing and mature follicles; Estradiol synthesized by granulosa cells; Theca cells produce androgens; Abnormalities include premature ovarian insufficiency (POI), ovarian failure, PCOS, and autoimmune ovarian disease
    • Uterus: Responds to estradiol by endometrial proliferation; Receives progesterone effects during luteal phase; Abnormal estradiol causes irregular bleeding, amenorrhea, or abnormal uterine bleeding; Estrogen-dependent endometrial pathology risk increases with abnormal hormone ratios
    • Fallopian Tubes: Function dependent on normal estradiol and progesterone levels; Impaired hormone signaling affects tube motility and egg transport; Severe hormone deficiency contributes to tubal dysfunction and infertility
    • Immune System: Target of autoimmune ovarian antibodies (AOA); Autoimmune ovarian disease leads to lymphocytic infiltration of ovaries; Associated with other autoimmune disorders; Presence of AOA indicates autoimmune-mediated ovarian dysfunction and inflammation
    • Adrenal Glands: Secondary source of androgen production; Interact with ovarian function through hormone cross-signaling; Adrenal dysfunction affects LH response and ovulation; PCOS often includes adrenal hyperandrogenism component
    • Thyroid Gland: Influences reproductive hormone metabolism and pituitary function; Thyroid disorders impair FSH/LH secretion and metabolism; Autoimmune thyroiditis often co-occurs with autoimmune ovarian disease; TSH elevation affects reproductive hormone balance
    • Associated Conditions: Premature ovarian insufficiency (POI) or failure; PCOS; Hypothyroidism affecting fertility; Cushing's syndrome altering hormone ratios; Hyperprolactinemia suppressing FSH/LH; Autoimmune ovarian failure; Primary amenorrhea; Secondary amenorrhea; Anovulation and infertility
  • Follow-up Tests
    • Estradiol Abnormalities: If low estradiol, measure estrone and estrogen metabolites to assess alternative pathway synthesis; Consider pelvic/transvaginal ultrasound to evaluate ovarian morphology; If elevated, perform LH and testosterone to rule out ovarian tumors
    • FSH Elevation (>8-10 mIU/mL day 3): Repeat FSH and estradiol on day 3 of next cycle for confirmation; Perform transvaginal ultrasound to assess antral follicle count (AFC); Measure AMH and inhibin-B for comprehensive ovarian reserve assessment; Consider repeat testing monthly if suspected POI
    • LH Abnormalities: If elevated with normal FSH, measure testosterone and DHEA-S to evaluate hyperandrogenism; Perform pelvic ultrasound to assess for PCOS features (ovarian cysts, increased stroma); Evaluate insulin resistance with fasting glucose and insulin
    • Low AMH (<1.0 ng/mL): Repeat AMH testing as single measurement may underestimate reserve; Perform transvaginal ultrasound for antral follicle counting; Consider genetic testing if <35 years old with low AMH; Discuss diminished ovarian reserve implications for fertility
    • High AMH (>4.0 ng/mL): Rule out PCOS with pelvic ultrasound and androgen testing; Measure free and total testosterone, DHEA-S; Assess metabolic parameters (glucose tolerance, lipid profile); Evaluate for insulin resistance
    • Low Inhibin-B (<43 pg/mL): Perform transvaginal ultrasound to assess antral follicles; Repeat day 3 testing in subsequent cycle for confirmation; Measure AMH and FSH for comprehensive reserve assessment; Consider referral to reproductive endocrinology for fertility evaluation
    • Positive Anti-Ovarian Antibody: Order anti-thyroid peroxidase (TPO) and anti-thyroglobulin antibodies to screen for autoimmune thyroiditis; Test anti-nuclear antibodies (ANA) and complement to assess systemic autoimmunity; Consider referral to immunology for management of autoimmune disease
    • General Follow-up: Repeat FSH/estradiol and inhibin-B annually if abnormal results or at baseline; Monitor AMH every 1-2 years for ovarian reserve surveillance; Transvaginal ultrasound with AFC assessment recommended if initial hormones abnormal; TSH and prolactin if FSH/LH abnormalities without other explanation
    • Complementary Tests: Transvaginal ultrasound for AFC and ovarian volume; Pelvic ultrasound for uterine and endometrial assessment; Hysterosalpingography (HSG) or sonohysterography for tubal patency; Semen analysis for male partner if infertility concern; Karyotype testing if suspected genetic abnormality with low ovarian reserve
    • Monitoring Frequency: Monthly testing during fertility treatment cycles; Every 1-3 months if adjusting hormone replacement therapy; Annual surveillance if known ovarian reserve decline; More frequent testing if POI confirmed; Every 6-12 months if managing PCOS with hormonal therapy
  • Fasting Required?
    • No fasting required: Female Hormone Profile tests can be drawn in non-fasting state as hormones are not affected by food intake
    • Normal meal and hydration: Patient may eat and drink normally prior to blood draw; Adequate hydration recommended to facilitate venipuncture
    • Medication considerations: Hormonal contraceptive use should be disclosed as it suppresses FSH, LH, and estradiol; Hormone replacement therapy (HRT) use must be documented; Medications affecting pituitary function (dopamine agonists, antipsychotics, metoclopramide) should be noted
    • Cycle timing critical: Testing should occur days 3-5 of menstrual cycle for basal hormone assessment; Day 1 = first day of bleeding; If cycle irregular, testing at any time acceptable for AMH but suboptimal for others
    • Patient preparation: Arrive calm and well-rested; Extreme stress may temporarily affect hormone values; Strenuous exercise within 2 hours before testing should be avoided; Early morning collection (8-10 AM) preferred for consistent hormone measurement
    • Cycle discontinuation: If on hormonal contraceptives or HRT, ideally stop 4-6 weeks before testing for accurate ovarian function assessment; If testing required while on hormones, results must be interpreted as suppressed baseline values
    • Thyroid/prolactin evaluation: If TSH abnormality suspected, coordinate testing on same day; Prolactin measurement should occur at least 3-4 hours after waking to minimize diurnal variation
    • Special circumstances: If amenorrheic, testing can be performed any time; After recent miscarriage, wait 4-6 weeks for hormone normalization; Following recent childbirth, wait 6-8 weeks postpartum for baseline hormones; During breastfeeding, hormones remain suppressed
    • Documentation: Patient should note cycle day, current medications, recent procedures or surgery, and any recent stressors; Confirmation of pregnancy/lactation status important; List of all supplements and herbal products helps interpret results

How our test process works!

customers
customers